Intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) agents has revolutionized the treatment of many retinal diseases, including age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and myopic choroidal neovascularization, and became the most common intraocular procedure worldwide [1]. This evidence concerns the gene VEGFA and retinal vein occlusion.